Theravance Biopharma, Inc. Impairment of Long-Lived Assets to be Disposed of
Theravance Biopharma, Inc. (TBPH) reported Impairment of Long-Lived Assets to be Disposed of of $4.51 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf · last filed 2025-08-13
- Theravance Biopharma, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2024-12-31 was $0.00.
- Theravance Biopharma, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2024-09-30 was $1.56M.
- Theravance Biopharma, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2024-06-30 was $2.95M.
- Theravance Biopharma, Inc. impairment of long-lived assets to be disposed of for fiscal 2024 was $4.51M.
- Theravance Biopharma, Inc. impairment of long-lived assets to be disposed of for fiscal 2021 was $0.00.
- Theravance Biopharma, Inc. impairment of long-lived assets to be disposed of for fiscal 2020 was $0.00.
- Theravance Biopharma, Inc. impairment of long-lived assets to be disposed of for fiscal 2019 was $0.00.
| Period end | Impairment of Long-Lived Assets to be Disposed of 3 month | Impairment of Long-Lived Assets to be Disposed of 6 month | Impairment of Long-Lived Assets to be Disposed of 9 month | Impairment of Long-Lived Assets to be Disposed of 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $1.56M derived: sum of 2 quarters · filed 2025-03-07 | $4.51M derived: sum of 3 quarters · filed 2025-08-13 | $4.51M 10-K · filed 2025-03-07 |
| 2024-09-30 | $1.56M 10-Q · filed 2024-11-14 | $4.51M derived: sum of 2 quarters · filed 2025-08-13 | $4.51M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $2.95M 10-Q · filed 2025-08-13 | $2.95M 10-Q · filed 2025-08-13 | ||
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |